Replies to post #328186 on Amarin Corp Plc (AMRN)

[Number sleven]

Kiwi, Yes. That should no longer hold. Vascepa does not have those issues. After doctors are educated they should never consider lovava over Vascepa. This is an issue that Amarin nerds to address.
Sleven,

[HinduKush]

I think you are going to see evidence at ACC 2021 that DHA containing drugs like Lovaza and Epanova directly negate the clinical benefits of EPA, independent of any change in LDL. This "give statin to neutralize LDL rise of Lovaza" is spurious reasoning. This is because while we do have a correlation of LDL levels and CV event rates, the CV clinical benefit of Vascepa IPE which was both considerable and statistically significant in REDUCE-IT had no correlation whatsoever with LDL levels or TG levels or HS CRP levels--this was a unique direct biological effect of the EPA. By analogy, the detrimental effect of DHA is a direct one that interferes with the beneficial biological effects of EPA. There is no other way to explain the lack of clinical benefit of DHA/EPA combo drugs in every clinical trial thus far, most especially STRENGTH.
HK